Trotter, Matthew William Burnell,Risueno-Perez, Alberto,Pourdehnad, Michael,Gandhi, Anita,Hagner, Patrick
申请号:
AU2016326499
公开号:
AU2016326499A1
申请日:
2016.09.22
申请国别(地区):
AU
年份:
2018
代理人:
摘要:
In one aspect, provided herein are methods for predicting the responsiveness of DLBCL patients to treatment with lenolidomide or Compound A; or a stereoisomer thereof; or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate thereof; or a polymorph thereof utilizing biomarkers or classfiers that correlate with responsiveness to one of these drugs. In another aspect, provided herein are methods for treating a DLBCL patient determined to be responsive to treatment with lenolidomide or Compound A; or a stereoisomer thereof; or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate thereof; or a polymorph thereof utilizing biomarkers or classifiers (or output thereof) that correlate with responsiveness to one of these drugs.